DE2803869C2 - Injizierbare Embolisations- und Okklusionslösung - Google Patents
Injizierbare Embolisations- und OkklusionslösungInfo
- Publication number
- DE2803869C2 DE2803869C2 DE2803869A DE2803869A DE2803869C2 DE 2803869 C2 DE2803869 C2 DE 2803869C2 DE 2803869 A DE2803869 A DE 2803869A DE 2803869 A DE2803869 A DE 2803869A DE 2803869 C2 DE2803869 C2 DE 2803869C2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- prolamine
- solution according
- zein
- viscosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000010102 embolization Effects 0.000 title claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 38
- 229920002494 Zein Polymers 0.000 claims description 20
- 239000005019 zein Substances 0.000 claims description 20
- 229940093612 zein Drugs 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002872 contrast media Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 239000000941 radioactive substance Substances 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 50
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 108060006613 prolamin Proteins 0.000 description 13
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 9
- 206010033645 Pancreatitis Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 5
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 5
- 229950005811 sodium amidotrizoate Drugs 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 206010033647 Pancreatitis acute Diseases 0.000 description 4
- 201000003229 acute pancreatitis Diseases 0.000 description 4
- -1 alkyl cyanoacrylates Chemical class 0.000 description 4
- 229940039231 contrast media Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 210000000277 pancreatic duct Anatomy 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000010104 catheter embolization Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 206010003226 Arteriovenous fistula Diseases 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000002729 catgut Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000021331 vascular occlusion disease Diseases 0.000 description 2
- NOVZFMNCTCKLPF-UHFFFAOYSA-N 2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(OCCC)=C(N2CC2)C(=O)C(OCCC)=C1N1CC1 NOVZFMNCTCKLPF-UHFFFAOYSA-N 0.000 description 1
- QMQFFHSJUJDRPG-UHFFFAOYSA-N 3-amino-2,4,6-triiodobenzoic acid Chemical compound NC1=C(I)C=C(I)C(C(O)=O)=C1I QMQFFHSJUJDRPG-UHFFFAOYSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001658031 Eris Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010019393 Fibrin Foam Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000000407 Pancreatic Cyst Diseases 0.000 description 1
- 208000006809 Pancreatic Fistula Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034246 Pelvic fractures Diseases 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038460 Renal haemorrhage Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Chemical class O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0452—Solutions, e.g. for injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2803869A DE2803869C2 (de) | 1978-01-30 | 1978-01-30 | Injizierbare Embolisations- und Okklusionslösung |
| AU43430/79A AU525929B2 (en) | 1978-01-30 | 1979-01-17 | Injectable embolization and occlusion solution |
| JP730879A JPS54123281A (en) | 1978-01-30 | 1979-01-26 | Embolus that can be injected and blockade solution |
| NL7900649A NL191433C (nl) | 1978-01-30 | 1979-01-26 | Injecteerbare emboliserings- en afsluitingssamenstelling. |
| AT0065679A AT363599B (de) | 1978-01-30 | 1979-01-29 | Verfahren zur herstellung einer injektionsloesung fuer eine gezielte embolisation bzw. einen gezielten verschluss von organen, deren gefaesssystemen oder von blutgefaessen |
| FR7902217A FR2415464A1 (fr) | 1978-01-30 | 1979-01-29 | Solution embolisante et occlusive injectable, a base de prolamine |
| GB7903005A GB2014043B (en) | 1978-01-30 | 1979-01-29 | Injectable embolization and occlusion solution |
| CA320,450A CA1116088A (en) | 1978-01-30 | 1979-01-29 | Injectable embolization and occlusion solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2803869A DE2803869C2 (de) | 1978-01-30 | 1978-01-30 | Injizierbare Embolisations- und Okklusionslösung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2803869A1 DE2803869A1 (de) | 1979-08-02 |
| DE2803869C2 true DE2803869C2 (de) | 1983-12-29 |
Family
ID=6030689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2803869A Expired DE2803869C2 (de) | 1978-01-30 | 1978-01-30 | Injizierbare Embolisations- und Okklusionslösung |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS54123281A (en, 2012) |
| AT (1) | AT363599B (en, 2012) |
| AU (1) | AU525929B2 (en, 2012) |
| CA (1) | CA1116088A (en, 2012) |
| DE (1) | DE2803869C2 (en, 2012) |
| FR (1) | FR2415464A1 (en, 2012) |
| GB (1) | GB2014043B (en, 2012) |
| NL (1) | NL191433C (en, 2012) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0115549B1 (de) * | 1983-02-03 | 1987-11-25 | Ethicon, Inc. | Paste zur Blutstillung und temporären Defektüberbrückung bei Knochentrauma |
| EP0128578A1 (de) * | 1983-06-14 | 1984-12-19 | Byk Gulden Lomberg Chemische Fabrik GmbH | Ethanolische Kontrastmittelsuspensionen |
| CA1225585A (en) * | 1983-06-30 | 1987-08-18 | Maria T. Litvinova | Composition for embolization of blood vessels |
| US4680171A (en) * | 1985-03-15 | 1987-07-14 | William Shell | Visualization of a bloodstream circulation with biodegradable microspheres |
| DE19608278A1 (de) * | 1996-02-23 | 1997-08-28 | Schering Ag | Pharmazeutische Mittel enthaltend perfluoralkylhaltige Metallkomplexe, und ihre Verwendung in der Tumortherapie und interventioniellen Radiologie |
| US6180113B1 (en) | 1996-02-23 | 2001-01-30 | Schering Ag | Pharmaceutical agents that contain perfluoroalkyl-containing metal complexes |
| KR970069028A (ko) * | 1996-04-01 | 1997-11-07 | 김은영 | 화학색전용 에멀젼의 제조방법 |
| US6333020B1 (en) * | 1999-05-13 | 2001-12-25 | Micro Therapeutics, Inc. | Methods for treating AVM's using radio active compositions |
| DE10261694A1 (de) * | 2002-12-30 | 2004-07-15 | Brassel, Friedhelm, Prof. Dr.med. | Flüssiges Embolisat |
| WO2008034270A2 (de) * | 2006-09-18 | 2008-03-27 | Forim-X Ag | Röntgenkontrastmittel für die postmortale, experimentelle und diagnostische angiographie |
| CH712511B1 (de) * | 2006-09-18 | 2017-11-30 | Forim-X Ag C/O Prof Dr Med Richard Dirnhofer | Röntgenkontrastmittel für die postmortale, experimentelle und diagnostische Angiographie. |
| CN107935870A (zh) * | 2017-11-09 | 2018-04-20 | 华中药业股份有限公司 | 一种2‑甲氨基‑5‑氯二苯甲酮的合成方法 |
| CN113813392A (zh) * | 2021-10-23 | 2021-12-21 | 哈尔滨工业大学 | 一种仿血细胞药物载体的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB311382A (en) * | 1928-05-10 | 1930-08-07 | H A Metz Lab Inc | Improvements in or relating to the manufacture of spinal anaesthetic solutions |
| CA958642A (en) * | 1969-06-11 | 1974-12-03 | Milos Sovak | Contrast media for radiography |
-
1978
- 1978-01-30 DE DE2803869A patent/DE2803869C2/de not_active Expired
-
1979
- 1979-01-17 AU AU43430/79A patent/AU525929B2/en not_active Ceased
- 1979-01-26 JP JP730879A patent/JPS54123281A/ja active Granted
- 1979-01-26 NL NL7900649A patent/NL191433C/xx not_active IP Right Cessation
- 1979-01-29 AT AT0065679A patent/AT363599B/de not_active IP Right Cessation
- 1979-01-29 FR FR7902217A patent/FR2415464A1/fr active Granted
- 1979-01-29 GB GB7903005A patent/GB2014043B/en not_active Expired
- 1979-01-29 CA CA320,450A patent/CA1116088A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL191433B (nl) | 1995-03-01 |
| AU525929B2 (en) | 1982-12-09 |
| AU4343079A (en) | 1979-08-09 |
| NL7900649A (nl) | 1979-08-01 |
| NL191433C (nl) | 1995-07-04 |
| FR2415464B1 (en, 2012) | 1983-07-01 |
| FR2415464A1 (fr) | 1979-08-24 |
| CA1116088A (en) | 1982-01-12 |
| JPS54123281A (en) | 1979-09-25 |
| DE2803869A1 (de) | 1979-08-02 |
| GB2014043B (en) | 1982-08-11 |
| JPH0129774B2 (en, 2012) | 1989-06-14 |
| AT363599B (de) | 1981-08-10 |
| GB2014043A (en) | 1979-08-22 |
| ATA65679A (de) | 1981-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4268495A (en) | Injectable embolization and occlusion solution | |
| DE69126861T2 (de) | Lösung zur aufbewahrung roter blutzellen | |
| DE2803869C2 (de) | Injizierbare Embolisations- und Okklusionslösung | |
| DE60037500T2 (de) | Cyanoacrylate umfassend inhibitoren und ein trübungsmittel | |
| EP0123235B1 (de) | Mikropartikel und Gasblächen enthaltendes Ultraschall-Kontrastmittel | |
| DE69230670T2 (de) | Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten | |
| EP0122624B1 (de) | Mikropartikel und Gasbläschen enthaltendes Ultraschallkontrastmittel | |
| DE69735534T2 (de) | Flüssige embolisationsmittel aus teilweise hydrolysiertem polyvinylacetat | |
| DE69003229T2 (de) | Entzündungshemmendes Mittel in einer Zusammensetzung. | |
| EP0365467B1 (de) | Ultraschallkontrastmittel aus Gasbläschen und Fettsäure-enthaltenden Mikropartikeln | |
| DE69434274T2 (de) | Zusammensetzung zum regenerieren von gelenkknorpeln | |
| EP0131540A2 (de) | Ultraschallkontrastmittel sowie dessen Herstellung | |
| DE3415246A1 (de) | Mittel zum embolisieren von blutgefaessen | |
| DE3433328A1 (de) | Pharmazeutische zusammensetzung fuer die therapie peripherer arteriopathien | |
| DE1720120A1 (de) | Injizierbare Zusatzmittel,Verfahren ihrer Herstellung und Verwendung und neue medizinische Zusammensetzungen,die dieses Zusatzmittel enthalten | |
| DE69029012T2 (de) | Stabile und lyophilisierte Zusammensetzung von Polyhematoporphyrinester oder -äther | |
| DE2326600C2 (en, 2012) | ||
| DE69813200T2 (de) | Verbesserung der wundheilung mit cm101/gbs-toxin | |
| EP0108820B1 (de) | Infusionslösungen zur Herztherapie | |
| EP0328957B1 (de) | Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen Substanz | |
| DE69021289T2 (de) | Angiographisches Adjuvans. | |
| DE3037299A1 (de) | Verfahren zur herstellung von chondroitinsulfat | |
| DE1767285B2 (de) | Verfahren zur Herstellung eines stabilen, hochwirksamen AHF-Konzentrates und Mittel zur Behandlung der Hämophilie | |
| CH641044A5 (de) | Prostacyclin und prostacyclin-derivate enthaltende pharmazeutische zubereitung und verfahren zu ihrer herstellung. | |
| DE60009525T2 (de) | Herstellung eines medikamentes zur verbesserten heilung des sternums nach einer sternotomie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. VOSSIUS, D., |
|
| 8126 | Change of the secondary classification |
Free format text: A61K 49/02 A61K 49/04 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |